GlassScriptPhysician profile
Kina C Hooks
NPI 1851941397
$6,701.54
in general payments reported to CMS, 2019-2025
26 companies · $1,978 in 2025
The $1,978 reported for 2025 was more than what 92% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,390 · 2022: $549 · 2023: $1,458 · 2024: $1,327 · 2025: $1,978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,763.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,762.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,986.46 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,128.60 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $592.45 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $431.53 | 2021-2025 | Austedo Xr, Uzedy |
| Corium, LLC | $404.95 | 2021-2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $317.01 | 2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $223.25 | 2023-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $219.26 | 2021-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $207.44 | 2022-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $206.17 | 2022-2025 | Auvelity, Sunosi |
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $124.77 | 2021-2025 | Spravato |
| Lundbeck LLC | $124.48 | 2021-2025 | Rexulti |
| Indivior INC. | $95.76 | 2023-2024 | Perseris |
| Jazz Pharmaceuticals INC. | $85.14 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $82.83 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $78.35 | 2021-2024 | Trintellix |
| Sunovion Pharmaceuticals INC. | $62.81 | 2021 | |
| Supernus Pharmaceuticals, INC. | $49.34 | 2023-2025 | Qelbree, Qelbree |
| Adlon Therapeutics L.P. | $42.33 | 2021 | |
| Allergan, INC. | $29.99 | 2021 | |
| Bausch Health US, LLC | $25.02 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.66 | 2021 | |
| Neos Therapeutics, LP | $14.90 | 2025 | Exxua |
| Ironshore Pharmaceuticals INC. | $14.04 | 2023 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $14.00 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kina Hooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.